Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 13,988 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark Goldsmith sold 13,988 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $2,786,969.12. Following the completion of the transaction, the insider directly owned 253,342 shares in the company, valued at $50,475,860.08. This represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Trading Down 3.0%

Shares of NASDAQ:RVMD opened at $190.95 on Friday. Revolution Medicines, Inc. has a 52-week low of $42.18 and a 52-week high of $224.31. The stock has a market cap of $40.93 billion, a price-to-earnings ratio of -21.65 and a beta of 1.40. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average price of $199.57 and a 200-day moving average price of $159.57.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the business earned ($1.31) earnings per share. Equities analysts predict that Revolution Medicines, Inc. will post -8.87 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on RVMD shares. UBS Group upped their price objective on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a report on Friday, August 28th. Wedbush raised their target price on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Stifel Nicolaus boosted their target price on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Sanford C. Bernstein upped their price target on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a report on Friday, August 21st. Finally, Truist Financial upped their price target on shares of Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $226.17.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Revolution Medicines recently received regulatory approval for a new medicine, validating its approach to treating certain cancers. The treatment could potentially become the most-prescribed therapy in its indication, improving the company’s long-term commercial outlook. Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
• Neutral Sentiment: A comparison article weighing Axsome Therapeutics against Revolution Medicines highlights RVMD as a healthcare investment candidate, but does not provide a clearly new company-specific catalyst. Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
• Negative Sentiment: Five company insiders, including the CFO and COO, collectively sold approximately $5.8 million of RVMD shares at $199.24 apiece. The filings state that the transactions were made to cover tax withholding obligations tied to vested equity awards, rather than for discretionary reasons. Nevertheless, the cluster of sales can create short-term supply and sentiment pressure. The insiders continued to hold substantial positions after the transactions. Revolution Medicines insider transaction filing

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Equitable Holdings Inc. acquired a new stake in shares of Revolution Medicines during the 2nd quarter valued at about $963,000. State of Wyoming purchased a new position in shares of Revolution Medicines in the 2nd quarter valued at about $1,769,000. Handelsbanken Fonder AB raised its holdings in Revolution Medicines by 243.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock worth $39,755,000 after purchasing an additional 150,500 shares during the period. Eagle Health Investments LP acquired a new position in Revolution Medicines in the 4th quarter worth about $9,231,000. Finally, Bank of New York Mellon Corp acquired a new position in Revolution Medicines in the 2nd quarter worth about $112,566,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.